Abeona Therapeutics Inc vs Boston Scientific Corporation — how do they compare? Abeona Therapeutics Inc trades at $7.49 (market cap $421.19M), while Boston Scientific Corporation trades at $50.48 (market cap $74.19B). The key difference: Boston Scientific Corporation is far larger — about 176.1× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| ABEO | BSX | |
|---|---|---|
Market Cap | $421.19M | $74.19B |
Sector | Health | Health |
52-Week High | $7.45 | $108.14 |
52-Week Low | $4.17 | $42.63 |
Enterprise Value | $276.10M | $86.27B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
BSX trades at $50.46, up 2.33% today, with strong earnings beats in recent quarters and a bullish technical trend. Revenue grew to $20.07B in 2025, with net income margin expanding to 17.5%. The stock shows robust institutional support and insider buying, while facing near-term headwinds from competitive pressures in key segments like WATCHMAN.
Outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target, implying 33% upside. Risks include guidance cuts and market share losses, but solid cash flow and valuation metrics support long-term growth potential for patient investors.
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →